U.S. Markets closed


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
4.0600-0.0900 (-2.17%)
At close: 5:35PM CEST


60 Avenue Rockefeller
Lyon 69008
33 4 78 74 44 38

Full Time Employees206

Key Executives

NameTitlePayExercisedYear Born
Mr. Gil Beyen BVBACEO & Director591.35kN/A1962
Mr. Eric Soyer Ph.D.CFO, COO & Deputy GM363.83kN/A1966
Dr. Jérôme Bailly Pharm.D.Deputy GM of Operations, Chief Quality Officer & Qualified Person228.9kN/A1979
Dr. Stewart CraigChief Technical OfficerN/AN/A1962
Naomi EichenbaumDirector Investor RelationsN/AN/AN/A
Mr. Brian SchwabVP of Legal Affairs & Gen. CounselN/AN/A1965
Ms. Anne-Cécile FumeyHR DirectorN/AN/A1975
Dr. Iman El-Hariry M.D., Ph.D.Chief Medical OfficerN/AN/A1960
Mr. Jean-Sebastien CleiftieChief Bus. OfficerN/AN/A1973
Dr. Philip L. LorenziConsultant & Member of Scientific BoardN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.

Corporate Governance

ERYTECH Pharma S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.